<DOC>
	<DOCNO>NCT00000135</DOCNO>
	<brief_summary>To evaluate efficacy safety human anti-CMV monoclonal antibody , MSL-109 , adjunct therapy control CMV retinitis .</brief_summary>
	<brief_title>Studies Ocular Complications AIDS ( SOCA ) -- Monoclonal Antibody CMV Retinitis Trial ( MACRT )</brief_title>
	<detailed_description>CMV retinitis common intraocular infection patient AIDS estimate affect 35 40 percent patient AIDS . Untreated CMV retinitis progressive disorder , end result total retinal destruction blindness . As September 1996 , drug approve United States Food Drug Administration ( FDA ) treatment CMV retinitis ganciclovir ( Cytovene ) , foscarnet ( Foscavir ) , cidofovir ( Vistide ) . All systemically administer anti-CMV drug give similar fashion consist initial 2-week high-dose treatment ( induction ) control infection follow long-term low dose treatment ( maintenance ) prevent relapse . Ganciclovir available intravenous oral formulation , foscarnet intravenous formulation , cidofovir give intermittent intravenous administration . A surgically implanted intraocular sustained-release ganciclovir device ( Vitrasert ) also approve FDA treatment CMV retinitis . Despite use continuous maintenance therapy , give enough time , patient CMV retinitis systemically administer drug relapse . Preliminary study suggest anti-CMV monoclonal antibody , MSL-109 , administer conjunction ganciclovir , markedly prolonged time relapse . Therefore , randomize control clinical trial evaluate MSL-109 adjunct therapy conduct . The MACRT randomize , placebo-controlled , multicenter clinical trial evaluate efficacy safety MSL-109 adjunct therapy treatment CMV retinitis . Patients CMV retinitis , newly diagnose suffer relapse active retinitis , eligible . Primary therapy ( e.g. , ganciclovir , foscarnet , etc . ) determine treat local physician . The patient enrol trial randomize either MSL-109 placebo , administer rapid intravenous infusion every 2 week . Outcomes include survival , retinitis progression , change amount retinal area involve CMV , loss visual function ( acuity field ) , morbidity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : 13 year old entry Diagnosis AIDS accord Centers Disease Control Prevention ( CDC ) definition Diagnosis active CMV retinitis determine SOCAcertified ophthalmologist time enrollment At least one lesion whose size onequarter optic disc area Currently receiving ( relapsed patient ) schedule receive ( newly diagnose patient ) drug primary treatment CMV retinitis contraindicate use MSL109 Visual acuity , least one eye meet eligibility criterion , 3 letter ETDRS chart 1 meter distance ( Snellen equivalent 5/200 ) . Patients poorer visual acuity may enrol visual acuity impairment possibly reversible ( eg , due optic disc edema ) vision least light perception eye Karnofsky score 60 Willingness ability , assistance caregiver necessary , comply treatment follow procedure sign consent statement Exclusion criterion : Current treatment intravenous immune globulin ( IVIG ) , CMV immune globulin ( CMVIG ) , alphainterferon ( alphaIFN ) , gammainterferon ( gammaIFN ) interleukin2 ( IL2 ) Media opacity precludes visualization fundus eye meet eligibility criterion Active medical problem , include drug alcohol abuse , consider sufficient hinder compliance treatment follow procedure Retinal detachment , schedule surgical repair , eye meet eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>